Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084447 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL30158158 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL16925392 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL19641298 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL21918484 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL29467488 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL18392338 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL16925331 | 1.00 | NAMPT (0.37) | NAMPTEPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL21952182 | 0.89 | PPM1D (0.32) | — | |
| SCHEMBL21856128 | 0.89 | PPM1D (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | PTPN11, PPM1F, PTPRF | NAMPT 388/4885EPHX2 2404/4885GPR119 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.